Plutux
$0.27
+0.37%
2026-09-01 16:00:00 EDT+$0.00
Healthcare
Drug Manufacturers - Specialty & Generic
NASDAQ
Active Trading

Operating from Chengdu, People's Republic of China, BGM Group Ltd. engages in the manufacturing and supply of active pharmaceutical ingredients (APIs), traditional ...

Price Action

$0.27
+0.37%+$0.00
High
Low
52W High-97.7%
Rel. vol
Interval
Range2.7h
VolumeSMA5SMA10
BGM Group Ltd. (NASDAQ: BGM) is a holding company with its main operating activities based in mainland China, operating through PRC entities (including a WFOE/VIE structure referenced in filings). The company focuses on the production and supply of pharmaceutical and related chemical products—particularly drug “raw materials” and intermediates—where consistent quality, ...BGM Group Ltd. (NASDAQ: BGM) is a holding company with its main operating activities based in mainland China, operating through PRC entities (including a WFOE/VIE structure referenced in filings). The company focuses on the production and supply of pharmaceutical and related chemical products—particularly drug “raw materials” and intermediates—where consistent quality, sourcing, and manufacturing capability are important for downstream drug makers. From a business standpoint, BGM’s portfolio is oriented around specialty and generic healthcare inputs. The company’s healthcare offering includes antibiotic-related products such as oxytetracycline (including both finished forms like tablets and API/supply forms for pharmaceutical manufacturers). It also supplies plant-based and TCM-derived items. A notable example in the provided description is a licorice-based range, including products such as Gan Di Xin (for cough/expectorant relief), Qilian Shan licorice extract variants used as ingredients or raw material for conventional licorice tablets and oral solutions, and associated extract products. Beyond antibiotics and licorice/TCM derivatives, BGM also provides heparin-related products used in pharmaceutical development for cardiovascular and cerebrovascular indications and hemodialysis contexts (as described). In addition to healthcare inputs, the company’s materials and manufacturing footprint extends into some natural food/agri-adjacent products—such as culinary sausage casings—plus organic and organic-inorganic fertilizer products marketed for agricultural use. This mix suggests BGM participates in manufacturing categories where chemical/biological processing and supply-chain execution can be leveraged across related product lines. In terms of scale and footprint, the provided dataset indicates full-time employees of about 323 (placing it in the 201–500 range). Financially, the dataset shows negative profitability measures on a trailing-twelve-month basis (e.g., negative net/operating margins and negative free cash flow metrics), while margins for gross profit are reported as positive (gross profit margin around 12.8%)—implying that operating expenses and/or other costs have been heavier relative to gross profit. Liquidity ratios are provided (e.g., current ratio above 1 in the dataset), indicating short-term obligations are not immediately extreme based on that snapshot. Key people in the provided sources include CEO Chen Xin. The company’s stated history includes establishment in 2019 (with later name changes), and its IPO date is listed as January 12, 2021. Overall, BGM appears positioned to serve downstream pharmaceutical and medical product manufacturers by supplying specialized APIs and TCM/heparin-related inputs, with operational structure typical of a cross-border holding model. Future “wishes” or priorities for such firms typically center on sustaining regulatory compliance, improving margins and cash generation, scaling reliable production capacity, and broadening customer adoption of its specialty raw-material products—though specific guidance is not included in the provided data.
Founded
2019
Employees
298
CEO
Chen Xin
Full Name
BGM Group Ltd.
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
ROE
-5.37%
Market Cap
$0.10B
Current Ratio
1.25
WACC
12.55%
ROIC
-3.71%

Contact Information

86 28 6477 5180
No. 152 Hongliang East 1st Street, Chengdu, SIC 610200

Related stocksDrug Manufacturers - Specialty & Generic

Browse all US stocks

Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer

© Plutux Technology Limited 2026